Clinical trial demonstrates that rilonacept significantly reduces gout flares
A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trialthe ...
Jan 5, 2012
0
0